JP2007511603A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511603A5 JP2007511603A5 JP2006541086A JP2006541086A JP2007511603A5 JP 2007511603 A5 JP2007511603 A5 JP 2007511603A5 JP 2006541086 A JP2006541086 A JP 2006541086A JP 2006541086 A JP2006541086 A JP 2006541086A JP 2007511603 A5 JP2007511603 A5 JP 2007511603A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- hydrogen
- compound
- formula
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000004434 sulfur atom Chemical group 0.000 claims 5
- 230000006735 deficit Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 235000019788 craving Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 210000000225 synapse Anatomy 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- VJFXSWNDOLSMOC-UHFFFAOYSA-N CSC1C(CC2)CCN2C1 Chemical compound CSC1C(CC2)CCN2C1 VJFXSWNDOLSMOC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0303075A SE0303075D0 (sv) | 2003-11-19 | 2003-11-19 | 4-substituted imidazoles |
| PCT/SE2004/001660 WO2005049612A1 (en) | 2003-11-19 | 2004-11-15 | 4-substituted imidazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511603A JP2007511603A (ja) | 2007-05-10 |
| JP2007511603A5 true JP2007511603A5 (enExample) | 2007-11-22 |
Family
ID=29729099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541086A Pending JP2007511603A (ja) | 2003-11-19 | 2004-11-15 | ４−置換イミダゾール類 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7384954B2 (enExample) |
| EP (1) | EP1687303A1 (enExample) |
| JP (1) | JP2007511603A (enExample) |
| KR (1) | KR20060100426A (enExample) |
| CN (1) | CN1882584A (enExample) |
| AU (1) | AU2004291457A1 (enExample) |
| BR (1) | BRPI0416629A (enExample) |
| CA (1) | CA2546096A1 (enExample) |
| IL (1) | IL175438A0 (enExample) |
| NO (1) | NO20062862L (enExample) |
| SE (1) | SE0303075D0 (enExample) |
| WO (1) | WO2005049612A1 (enExample) |
| ZA (1) | ZA200604018B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0303076D0 (sv) * | 2003-11-19 | 2003-11-19 | Astrazeneca Ab | 5-substituted imidazoles |
| JP2008524212A (ja) * | 2004-12-16 | 2008-07-10 | アストラゼネカ・アクチエボラーグ | ニコチン性アセチルコリン受容体リガンド |
| FR2974365B1 (fr) | 2011-04-20 | 2017-08-25 | Centre Nat De La Rech Scient (C N R S) | 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ226000A (en) * | 1987-09-10 | 1991-06-25 | Merck Sharp & Dohme | Oxadiazolyl-azabicycloheptanes and pharmaceutical compositions |
| WO2002015662A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| JP2004506734A (ja) * | 2000-08-21 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリド置換ヘテロアリール部分 |
| US20020086871A1 (en) * | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
| FR2832713B1 (fr) * | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| EP1562945B1 (en) | 2002-11-11 | 2006-11-15 | Neurosearch A/S | 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof |
-
2003
- 2003-11-19 SE SE0303075A patent/SE0303075D0/xx unknown
-
2004
- 2004-11-15 US US10/579,609 patent/US7384954B2/en not_active Expired - Fee Related
- 2004-11-15 AU AU2004291457A patent/AU2004291457A1/en not_active Abandoned
- 2004-11-15 BR BRPI0416629-9A patent/BRPI0416629A/pt not_active IP Right Cessation
- 2004-11-15 WO PCT/SE2004/001660 patent/WO2005049612A1/en not_active Ceased
- 2004-11-15 EP EP04800323A patent/EP1687303A1/en not_active Withdrawn
- 2004-11-15 CN CNA2004800342450A patent/CN1882584A/zh active Pending
- 2004-11-15 JP JP2006541086A patent/JP2007511603A/ja active Pending
- 2004-11-15 CA CA002546096A patent/CA2546096A1/en not_active Abandoned
- 2004-11-15 KR KR1020067009700A patent/KR20060100426A/ko not_active Withdrawn
-
2006
- 2006-05-04 IL IL175438A patent/IL175438A0/en unknown
- 2006-05-18 ZA ZA200604018A patent/ZA200604018B/en unknown
- 2006-06-19 NO NO20062862A patent/NO20062862L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507241A5 (enExample) | ||
| RU2372350C2 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2-(1-АЗА-БИЦИКЛО[2.2.2]ОКТ-3-ИЛ)-2,3-ДИГИДРОИЗОИНДОЛ-1-ОНА/5,6-ДИГИДРО-ФУРО[2,3-c]ПИРРОЛ-4-ОНА В КАЧЕСТВЕ ЛИГАНДОВ К АЛЬФА 7 НИКОТИНОВОМУ АЦЕТИЛХОЛИНОВОМУ РЕЦЕПТОРУ | |
| AU2014241759B2 (en) | Substituted naphthyridine and quinoline compounds as MAO inhibitors | |
| JP2007532637A5 (enExample) | ||
| JP2003513071A5 (enExample) | ||
| JP2003523342A5 (enExample) | ||
| JP2003513073A5 (enExample) | ||
| JP2011517443A5 (enExample) | ||
| JP2019532079A5 (enExample) | ||
| RU2001122812A (ru) | Новые аралкиламины спирофуропиридинов, полезные в терапии | |
| JP2005527588A5 (enExample) | ||
| ATE451373T1 (de) | N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung | |
| JP2006506462A5 (enExample) | ||
| CN110366555A (zh) | 甾族类衍生物调节剂、其制备方法和应用 | |
| CA2482311A1 (en) | Furyl compounds | |
| JP2015516429A5 (enExample) | ||
| CN103570722A (zh) | 稠环哒嗪酮类化合物及其制备方法和用途 | |
| JP2007515479A5 (enExample) | ||
| AU2017208119B2 (en) | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | |
| WO2016065222A1 (en) | Tricyclic atropisomer compounds | |
| CA3063938A1 (en) | Compounds, compositions and methods | |
| WO2005044818A2 (en) | Imidazo[1,2-a]pyridine anxiolytics | |
| RU2006125636A (ru) | Лиганды никотиновых рецепторов ацетилхолина | |
| CN106456645B (zh) | 用于放射性标记的方法和试剂 | |
| HRP20100622T1 (hr) | Novi derivati cikloalkiliranog benzotiadizina, postupak njihove priprave i farmaceutski pripravci koji ih sadrže |